David J. Matson - Concepedia

Author

David J. Matson

Amgen (United States)

Also Known As

David J Matson, David J. Matson, David Matson

Publications

782

Citations

H-Index

Concepts

All Affiliations

Amgen (United States)Wren Laboratories (United States)

About

David J. Matson is an author at Amgen (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	370
2	Biochemistry	4	4	195
3	Health Sciences	2	2	175
4	Natural Sciences	2	2	55
5	Anesthesia	1	1	15

David J. Matson

Publications

779

Citations

H-Index

Page 1

	Year	Citations
Global Nav1.7 Knockout Mice Recapitulate the Phenotype of Human Congenital Indifference to Pain Jacinthe Gingras, Sarah E. Smith, David J. Matson, PLoS ONE Pain MedicineImmunologyNeuropathic PainMolecular PainPain Syndrome	2014	160
Crystal structures of human glycine receptor α3 bound to a novel class of analgesic potentiators Xin Huang, P.L. Shaffer, Shawn Ayube, Nature Structural & Molecular Biology Molecular PharmacologyBiochemistryG Protein-coupled ReceptorMedicineReceptor (Biochemistry)	2016	122
Inflammation-Induced Reduction of Spontaneous Activity by Adjuvant: A Novel Model to Study the Effect of Analgesics in Rats David J. Matson, Daniel C. Broom, Susan R. Carson, Journal of Pharmacology and Experimental Therapeutics	2006	97
Characterization of N-(Adamantan-1-ylmethyl)-5-[(3 R-aminopyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X7 Antagonist in Animal Models of Pain and Inflammation Daniel C. Broom, David J. Matson, Elizabeth M. Bradshaw, Journal of Pharmacology and Experimental Therapeutics	2008	77
Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain Bao-Xi Gao, Markus Hierl, Kristie Clarkin, Pain	2010	65
Identification of a Potent, State-Dependent Inhibitor of Nav1.7 with Oral Efficacy in the Formalin Model of Persistent Pain Howard Bregman, Loren Berry, John L. Buchanan, Journal of Medicinal Chemistry	2011	54
Pharmacologic Characterization of AMG8379, a Potent and Selective Small Molecule Sulfonamide Antagonist of the Voltage-Gated Sodium Channel NaV1.7 Thomas Kornecook, Ruoyuan Yin, Stephen M. Altmann, Journal of Pharmacology and Experimental Therapeutics	2017	52
Discovery of Novel 6,6-Heterocycles as Transient Receptor Potential Vanilloid (TRPV1) Antagonists Charles A. Blum, Timothy M. Caldwell, Xiaozhang Zheng, Journal of Medicinal Chemistry Chronic Inflammatory PainPain MedicineNeuropathic PainMolecular PainPharmacotherapy	2010	37
New frontiers in assessing pain and analgesia in laboratory animals Daniel N. Cortright, David J. Matson, Daniel C. Broom Expert Opinion on Drug Discovery	2008	25
The discovery of benzoxazine sulfonamide inhibitors of NaV1.7: Tools that bridge efficacy and target engagement Daniel S. La, Emily A. Peterson, Christiane Bode, Bioorganic & Medicinal Chemistry Letters	2017	20

Page 1